-
Signature
-
/s/ Avraham S. Adler, Attorney-in-Fact
-
Stock symbol
-
PTCT
-
Transactions as of
-
Sep 8, 2025
-
Transactions value $
-
-$1,362,147
-
Form type
-
4
-
Date filed
-
9/9/2025, 05:00 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN |
/s/ Avraham S. Adler, Attorney-in-Fact |
2025-09-09 |
0001323212 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$515K |
+16.7K |
+22.9% |
$30.86 |
89.6K |
Sep 8, 2025 |
Direct |
F1, F2 |
| transaction |
PTCT |
Common Stock |
Sale |
-$951K |
-16.7K |
-18.63% |
$56.94 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F3 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$67.6K |
+6.02K |
+8.25% |
$11.23 |
78.9K |
Sep 8, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$342K |
-6.02K |
-7.62% |
$56.91 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F4 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$154K |
+8.53K |
+11.7% |
$18.01 |
81.4K |
Sep 8, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$485K |
-8.53K |
-10.47% |
$56.92 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F5 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$115K |
+3.71K |
+5.09% |
$30.86 |
76.6K |
Sep 8, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$211K |
-3.71K |
-4.85% |
$56.92 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F6 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$27K |
+2.41K |
+3.3% |
$11.23 |
75.3K |
Sep 8, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$137K |
-2.41K |
-3.19% |
$56.92 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F7 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$14K |
+1.24K |
+1.7% |
$11.32 |
74.2K |
Sep 8, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$70.4K |
-1.24K |
-1.67% |
$56.85 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F8 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$14.2K |
+1.25K |
+1.71% |
$11.32 |
74.2K |
Sep 8, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$71.1K |
-1.25K |
-1.69% |
$56.86 |
72.9K |
Sep 8, 2025 |
Direct |
F1, F9 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-16.7K |
-81.81% |
$0.00 |
3.71K |
Sep 8, 2025 |
Common Stock |
16.7K |
$30.86 |
Direct |
F1, F10 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-6.02K |
-71.44% |
$0.00 |
2.41K |
Sep 8, 2025 |
Common Stock |
6.02K |
$11.23 |
Direct |
F1, F10 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-8.53K |
-100% |
$0.00 |
0 |
Sep 8, 2025 |
Common Stock |
8.53K |
$18.01 |
Direct |
F1, F10 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-3.71K |
-100% |
$0.00 |
0 |
Sep 8, 2025 |
Common Stock |
3.71K |
$30.86 |
Direct |
F1, F10 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-2.41K |
-100% |
$0.00 |
0 |
Sep 8, 2025 |
Common Stock |
2.41K |
$11.23 |
Direct |
F1, F10 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-1.24K |
-49.76% |
$0.00 |
1.25K |
Sep 8, 2025 |
Common Stock |
1.24K |
$11.32 |
Direct |
F1, F10 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-1.25K |
-100% |
$0.00 |
0 |
Sep 8, 2025 |
Common Stock |
1.25K |
$11.32 |
Direct |
F1, F10 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: